Guolo F, et al. Blood Cancer J. 2020: Treatment with Vyxeos Liposomal in a compassionate use program
Discover the full outcomes of this multicentre cohort in Italy, where 71 patients were treated with Vyxeos Liposomal showing a 12-month OS of 68.6% and a manageable adverse events profile.1
Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.
Topics: Safety Vyxeos Liposomal Data